Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Non-cash Items (2017 - 2025)

Puma Biotechnology's Non-cash Items history spans 9 years, with the latest figure at $3.6 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 1053.04% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $3.6 million, up 1053.04%, while the annual FY2025 figure was $3.6 million, 1053.04% up from the prior year.
  • Non-cash Items reached $3.6 million in Q4 2025 per PBYI's latest filing, up from $3.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $4.3 million in Q1 2021 to a low of $145000.0 in Q3 2023.
  • Average Non-cash Items over 5 years is $2.2 million, with a median of $2.5 million recorded in 2021.
  • Peak YoY movement for Non-cash Items: crashed 95.96% in 2023, then skyrocketed 2585.5% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $1.1 million in 2021, then fell by 3.06% to $1.0 million in 2022, then rose by 5.64% to $1.1 million in 2023, then plummeted by 71.67% to $313000.0 in 2024, then soared by 1053.04% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Non-cash Items are $3.6 million (Q4 2025), $3.1 million (Q3 2025), and $3.6 million (Q2 2025).